All three candidate compounds mitigated cisplatin-induced apoptosis in vitro, providing further evidence that the HO-1 protein induced by these small molecules is not only functional, but that these compounds could also have potential to be used to mitigate the adverse kidney affects associated with cisplatin chemotherapy, which would be a great benefit to the approximately 25% of patients receiving cisplatin treatment for solid organ cancers that develop AKI or CKD. The gene discussed is HMOX1; the disease is chronic kidney disease.